BIOMARIN PHARMACEUTICAL INC Induced Conversion of Convertible Debt Expense
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Induced Conversion of Convertible Debt Expense of $0 for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2016-11-03
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for the quarter ending 2016-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for the quarter ending 2015-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for the quarter ending 2015-09-30 was $0.00.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for the quarter ending 2015-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for fiscal 2015 was $163.00K, a 75.82% decline from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for fiscal 2014 was $674.00K, a 94.80% decline from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for fiscal 2013 was $12.96M.
- BIOMARIN PHARMACEUTICAL INC induced conversion of convertible debt expense for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
| Period end | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month | Induced Conversion of Convertible Debt Expense 9 month | Induced Conversion of Convertible Debt Expense 12 month |
|---|---|---|---|---|
| 2016-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 10-Q · filed 2016-11-03 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $0.00 derived: sum of 3 quarters · filed 2016-11-03 | $163.00K 10-K · filed 2016-02-29 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $163.00K 10-Q · filed 2016-11-03 | $163.00K derived: sum of 4 quarters · filed 2016-11-03 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $163.00K 10-Q · filed 2016-08-08 | $163.00K derived: sum of 3 quarters · filed 2016-08-08 | $163.00K derived: sum of 4 quarters · filed 2016-08-08 |
| 2015-03-31 | $163.00K 10-Q · filed 2016-05-02 | $163.00K derived: sum of 2 quarters · filed 2016-05-02 | $163.00K derived: sum of 3 quarters · filed 2016-05-02 | $837.00K derived: sum of 4 quarters · filed 2016-05-02 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $674.00K derived: sum of 3 quarters · filed 2016-02-29 | $674.00K 10-K · filed 2016-02-29 |
| 2014-09-30 | $0.00 10-Q · filed 2014-10-28 | $674.00K derived: sum of 2 quarters · filed 2015-08-05 | $674.00K 10-Q · filed 2015-11-02 | $1.49M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $674.00K 10-Q · filed 2015-08-05 | $674.00K 10-Q · filed 2015-08-05 | $1.49M derived: sum of 3 quarters · filed 2016-02-29 | $3.22M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-02 | $813.00K derived: sum of 2 quarters · filed 2016-02-29 | $2.54M derived: sum of 3 quarters · filed 2016-02-29 | $2.54M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.54M derived: sum of 2 quarters · filed 2016-02-29 | $2.54M derived: sum of 3 quarters · filed 2016-02-29 | $12.96M 10-K · filed 2016-02-29 |
| 2013-09-30 | $1.73M 10-Q · filed 2014-10-28 | $1.73M derived: sum of 2 quarters · filed 2014-10-28 | $12.15M 10-Q · filed 2014-10-28 | $12.15M derived: sum of 4 quarters · filed 2014-10-28 |
| 2013-06-30 | $0.00 10-Q · filed 2014-07-31 | $10.42M 10-Q · filed 2014-07-31 | $10.42M derived: sum of 3 quarters · filed 2014-07-31 | $10.42M derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | $10.42M 10-Q · filed 2014-05-02 | $10.42M derived: sum of 2 quarters · filed 2014-05-02 | $10.42M derived: sum of 3 quarters · filed 2014-05-02 | $10.42M derived: sum of 4 quarters · filed 2014-05-02 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $0.00 derived: sum of 2 quarters · filed 2014-02-26 | $0.00 derived: sum of 3 quarters · filed 2014-02-26 | $0.00 10-K · filed 2014-02-26 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-28 | $0.00 derived: sum of 2 quarters · filed 2013-10-28 | $0.00 10-Q · filed 2013-10-28 | $0.00 derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-06-30 | $0.00 10-Q · filed 2013-07-29 | $0.00 10-Q · filed 2013-07-29 | $0.00 derived: sum of 3 quarters · filed 2014-02-26 | $1.90M derived: sum of 4 quarters · filed 2014-02-26 |
| 2012-03-31 | $0.00 10-Q · filed 2013-04-29 | $0.00 derived: sum of 2 quarters · filed 2014-02-26 | $1.90M derived: sum of 3 quarters · filed 2014-02-26 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $1.90M derived: sum of 2 quarters · filed 2014-02-26 | $1.90M 10-K · filed 2014-02-26 | |
| 2011-09-30 | $1.90M 10-Q · filed 2012-10-29 | $1.90M 10-Q · filed 2012-10-29 | ||
| 2010-12-31 | $13.73M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.73M derived: sum of 2 quarters · filed 2013-02-26 | $13.73M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $0.00 10-Q · filed 2011-10-31 | $0.00 10-Q · filed 2011-10-31 | ||
| 2009-12-31 | $0.00 10-K · filed 2012-02-22 | |||
| 2008-12-31 | $0.00 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |